Use of big data for drug safety monitoring and decision making
Journal of the Korean Medical Association
;
: 391-397, 2014.
Article
in Korean
| WPRIM
| ID: wpr-60718
ABSTRACT
The development of information technologies has led to the era of big data; such enormous collections of information on drugs and adverse drug reactions are stored in either a structured, a semistructured, or an unstructured form. Because of the nature of the emerging issue of drug safety, it is common for policy makers and healthcare professionals to make decisions without sufficient evidence. Big data may be used as an efficient pharmacovigilance tool, which enables us to recognize adverse drug reactions that may not have been identified in pre-marketing clinical trials, in order to capture the patterns of drug utilization and adverse events, and to predict the occurrence of adverse drug reactions. National surveillance systems using electronic health databases have been established successfully in the US and Europe. The Korea Institute of Drug Safety and Risk Management (KIDS) plans to establish a big data platform for pharmacovigilance in Korea. The big data may be effectively used for evidence-based regulatory and clinical decision making in the field of drug safety and risk management.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Risk Management
/
Administrative Personnel
/
Pharmacoepidemiology
/
Decision Making
/
Delivery of Health Care
/
Drug-Related Side Effects and Adverse Reactions
/
Drug Utilization
/
Europe
/
Pharmacovigilance
/
Korea
Type of study:
Etiology study
/
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
/
Europa
Language:
Korean
Journal:
Journal of the Korean Medical Association
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS